Table 1.
Participants’ demographics
| Demographics | PD-NC | PD-MCI | PDD | F/t/χ2 Value | P Value |
|---|---|---|---|---|---|
| Sex (No. Male) | 25/37 | 26/35 | 12/17 | 5.115 | 0.059 |
| Age | 69.74 ± 6.95 | 66.71 ± 6.86 | 75.78 ± 8.59 | 8.029 | 0.001 |
| Education, yr | 16.48 ± 4.05 | 15.76 ± 4.21 | 16.81 ± 3.03 | 0.523 | 0.568 |
| Levodopa equivalence | 374.17 ± 385.97 | 586.37 ± 421.17 | 753.61 ± 481.08 | 4.230 | 0.018 |
| UPDRS-III | 22.27 ± 9.03 | 23.75 ± 7.89 | 34.45 ± 6.28 | 8.469 | 0.0009 |
| Hoehn and Yahr | 2.16 ± 0.27 | 2.23 ± 0.56 | 2.75 ± 0.72 | 3.294 | 0.059 |
Values are expressed as means ± SD or fraction of participants. The high levodopa equivalence standard deviation indicates that the participants were spread out over a wide range of dosages. PDD, Parkinson’s disease dementia; PD-MCI, Parkinson’s disease mild cognitive impairment; PD-NC, Parkinson’s disease normal cognition; UPDRS, Unified Parkinson’s Disease Rating Scale. Bold type represents significant between-groups differences.